Study of a new drug for advanced tumors that test positive for egfr and pd-l1
Part of Cancer clinical trials.
This study tests a new drug called SM2275, given as an injection, for people with advanced solid tumors that have EGFR and PD-L1 markers. The goal is to see if the drug is safe and effective, and it might help if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be advanced or has spread, and it must test positive for EGFR and PD-L1 markers. Common types include head and neck cancer, non-small cell lung cancer, colorectal cancer, or kidney cancer.
- Standard treatments either didn't work, caused too many side effects, or aren't available for your situation.
- You need to have at least one measurable tumor (one that can be seen on scans) and be able to provide a tumor sample.
- You should be in fairly good health overall — able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your heart, liver, kidneys, and blood counts must be within acceptable ranges, and you must not have serious heart or lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new injectable drugs for advanced solid tumors, especially kidney, head and neck, cervical, and ovarian cancers. The goal is to see if the combination is safe and if it can shrink tumors.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new tablet called GEN-725 for people with advanced solid tumors that have stopped responding to standard treatments or cannot tolerate them. It aims to see if the drug is safe and how it affects the body, and may be an option if you've had prior treatment with PD-1/PD-L1 inhibitors that stopped working at least 6 months ago.
This trial tests a new drug called JSKN027 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this drug is safe and if it can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.